|
Synonyms: MGN-1703 | MGN1703
Compound class:
Nucleic acid
Comment: Lefitolimod (MGN-1703) is a CpG oligonucleotide that was intended to act as a Toll-like receptor 9 (TLR9) agonist to stimulate innate and adaptive immunity. It behaves as a double-stem loop immunomodulator, with CpG motifs at both ends.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| No information available. |
Summary of Clinical Use ![]() |
| Lefitolimod (MGN-1703) was progressed as an anti-tumour clinical candidate [2,5-6], and for anti-HIV potential [1,7]. Development of the asset was discontinued in 2020 following failure to demonstrate efficacy in phase 3 oncology studies and the collpase of its originator. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT03837756 | Combining TLR9 Agonist With bNAbs for Reservoir Reduction and Immunological Control of HIV | Phase 2 Interventional | University of Aarhus | ||
| NCT02077868 | Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment | Phase 3 Interventional | Mologen AG | ||
| NCT02668770 | Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies | Phase 1 Interventional | M.D. Anderson Cancer Center | 4 | |